Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
Sign Up to like & getrecommendations! Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.06.001
Abstract: BACKGROUND Pulmonary sarcomatoid carcinomas (PSCs) constitutes a heterogeneous group of NSCLCs, which show poor prognosis even with aggressive surgical treatment and postoperative chemotherapy. The detection MET exon14 skipping (METex14 skipping) in PSCs suggests the targeted… read more here.
Keywords: dna rna; rna based; metex14; metex14 skipping ... See more keywords
Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.9511
Abstract: 9511Background: METex14 SA are oncogenic drivers in NSCLC. Due to the numerous sites around ex14 that bind the spliceosome complex, many variations can result in deleterious alterations (alts). We ... read more here.
Keywords: nsclcs met; exon metex14; characterization 387; metex14 ... See more keywords
Evaluation of different MET genotypes as biomarkers for immunotherapy outcomes in NSCLC patients.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e21032
Abstract: e21032 Background: Previous studies suggested that MET exon 14 ( METex14) mutation regarding as a distinct subset was sensitive to MET-inhibitors, but poorly response to immunotherapy. Conversly, MET non-exon-14 (non-ex14) mutations including those undetermined functions… read more here.
Keywords: ex14 mutations; nsclc patients; met non; metex14 ... See more keywords